News
Prescient unveils its latest powerful platform to advance personalised targeted cancer treatments
Prescient is continuing to be a powerful force in the burgeoning personalised cancer treatment therapy sector, unveiling its latest platform to advance CAR-T therapy globally….
Article, News
Prescient unveils new platform after 18 months in stealth mode
Australian biotech company Prescient Therapeutics has publicly revealed its high-performing cell therapy enhancement platform named CellPryme-M, developed in collaboration with the Peter MacCallum Cancer Centre.
Article, News
Prescient Therapeutics unveils high performance cell therapy technology CellPryme-M
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has today unveiled the latest technology in its portfolio, a high-performance platform known as CellPryme-M which is designed to enhance…
Article, News
Prescient Therapeutics (ASX:PTX) unveils new cell therapy platform
Prescient Therapeutics (PTX) has unveiled its new cell therapy manufacturing enhancement technology, CellPryme-M. CellPryme-M is a platform technology that produces superior cells during the cell…
News
Prescient Therapeutics Are Developing Game-Changing Cancer Treatments
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins ASX Investor to discuss the company’s innovative cancer treatments with the Biotech…
News
Prescient (ASX: PTX) expands its PTX-200 trial in AML patients
Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company, has taken another step towards advancing its study of diseases of unmet medical needs. PTX will…
News
Cell therapies progress and strong cash position mark Prescient’s March quarter
Prescient Therapeutics (ASX: PTX) signed off the March quarter with major progress made in its Cell Therapy Enhancements and OmniCAR program. The clinical-stage oncology company made…
News
Fighting Back: 3 ASX cancer stocks giving hope in a leading cause of death
According to the World Health Organisation, cancer accounted for nearly 10 million deaths in 2020, or nearly one in six deaths. Here are 3 small…
News
‘Exciting clinical and commercial opportunity’: Prescient
next round of trials on its target therapy PTX-100 for blood cancers. The company completed the first round of its Phase 1b trials of the…
News
Prescient Therapeutics (ASX:PTX) starts enrolling patients for extended PTX-100 trial for lymphomas
Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company, has announced the opening of enrolment in the expansion cohort of the Phase 1b trial of…